Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 1-Year Low at $4.82

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP hit a new 52-week low during trading on Thursday . The stock traded as low as $4.82 and last traded at $4.87, with a volume of 115637 shares traded. The stock had previously closed at $4.91.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AUPH shares. HC Wainwright reiterated a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. Royal Bank of Canada dropped their price objective on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an "outperform" rating on the stock in a research note on Friday, February 16th. Cantor Fitzgerald dropped their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, February 23rd. Finally, Jefferies Financial Group dropped their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a "hold" rating on the stock in a research note on Friday, February 16th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Down 2.0 %

The firm's 50 day simple moving average is $5.62 and its 200 day simple moving average is $7.30. The company has a market cap of $695.62 million, a price-to-earnings ratio of -8.85 and a beta of 1.36. The company has a quick ratio of 4.99, a current ratio of 5.50 and a debt-to-equity ratio of 0.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The company had revenue of $45.10 million during the quarter, compared to the consensus estimate of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The company's revenue was up 58.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.18) earnings per share. Sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post -0.06 EPS for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in Aurinia Pharmaceuticals by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 1,798 shares during the period. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $30,000. Sunbelt Securities Inc. bought a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $31,000. Tidemark LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $39,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 54.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 1,142 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.